Volume 27, No 1, Jan 2017
ISSN: 1001-0602
EISSN: 1748-7838 2018
impact factor 17.848*
(Clarivate Analytics, 2019)
Volume 27 Issue 1, January 2017: 74-95
REVIEWS
Dendritic cell-based immunotherapy
Rachel L Sabado1, Sreekumar Balan1 and Nina Bhardwaj1
1The Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York City, NY 10029, USA
Correspondence: Nina Bhardwaj,(Nina.Bhardwaj@mssm.edu)
Immunotherapy using dendritic cell (DC)-based vaccination is an approved approach for harnessing the potential of a patient's own immune system to eliminate tumor cells in metastatic hormone-refractory cancer. Overall, although many DC vaccines have been tested in the clinic and proven to be immunogenic, and in some cases associated with clinical outcome, there remains no consensus on how to manufacture DC vaccines. In this review we will discuss what has been learned thus far about human DC biology from clinical studies, and how current approaches to apply DC vaccines in the clinic could be improved to enhance anti-tumor immunity.
10.1038/cr.2016.157
FULL TEXT | PDF
Browse 2734
